BPC-157 — Compound Profile

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide (15 amino acids) derived from a region of human gastric juice protein BPC. It is one of the more extensively characterized peptides in preclinical literature, with a substantial body of peer-reviewed publications examining its activity across multiple cell types and organ-system models.

Documented Preclinical Research Areas

• Nitric oxide (NO) signaling: BPC-157 has been shown to modulate eNOS expression and intracellular NO production in endothelial cell culture models, with downstream effects on vasoregulatory signaling
• Angiogenesis pathway studies: in vitro and in vivo preclinical models have documented interactions with VEGF signaling and capillary tube formation assays under controlled experimental conditions
• Gastrointestinal mucosal cytoprotection: BPC-157 has demonstrated cytoprotective activity in gastric and intestinal epithelial cell lines subjected to oxidative and cytotoxic challenge in experimental systems
• Connective tissue cell signaling: fibroblast and tenocyte culture studies have characterized BPC-157 interactions with TGF-beta and related growth factor receptor pathways
• Neuronal cell culture models: studies have examined BPC-157 effects on neurotrophic signaling, including interactions with dopaminergic and serotonergic pathway components in preclinical models
• Cytoprotective mechanism studies: preclinical research has documented protective activity against chemically induced cellular stress in multiple organ-system models

Signaling Pathways of Research Interest

BPC-157 research has primarily centered on the following molecular targets and pathways in model systems: endothelial nitric oxide synthase (eNOS) regulation; vascular endothelial growth factor (VEGF) receptor interactions; early growth response protein 1 (EGR-1) transcriptional activity; focal adhesion kinase (FAK) signaling in fibroblast migration studies; and selective modulation of cytochrome P450 enzyme activity in hepatocyte models.

TB-500 — Compound Profile

TB-500 is a synthetic peptide corresponding to the actin-binding region of Thymosin Beta-4 (Tbeta4), a 43-amino acid protein involved in regulating the ratio of filamentous (F-actin) to globular (G-actin) actin within cells. The active sequence LKKTETQ, retained in TB-500, is responsible for the G-actin sequestration activity that characterizes Tbeta4 function in cytoskeletal biology research.

Documented Preclinical Research Areas

• Actin dynamics: TB-500 is an established research tool for G-actin sequestration studies, lamellipodia formation assays, and investigations of actin treadmilling in fibroblast and endothelial cell systems
• Cell migration assays: TB-500 is used in scratch assay (wound-closure) models and Transwell chemotaxis assays to characterize directional cell motility and cytoskeletal polarization under defined experimental conditions
• Integrin-linked kinase (ILK) pathway studies: research has documented TB-500/Tbeta4 interactions with ILK, PI3K/Akt, and downstream regulators of cell survival signaling in preclinical models
• Extracellular matrix interaction studies: dermal fibroblast and mesenchymal cell lines have been used to characterize TB-500 effects on matrix metalloproteinase activity and ECM remodeling signaling
• Stem and progenitor cell mobilization: preclinical cardiac and hematopoietic models have examined Tbeta4 fragment activity on progenitor cell chemotaxis and homing signaling
• Angiogenic signaling: TB-500 has been studied for its contribution to endothelial cell tube formation and vascular sprouting in Matrigel assay systems, complementary to but mechanistically distinct from BPC-157 angiogenesis research